Symbol="ITOS"
AssetType="Common Stock"
Name="Iteos TherapeuticsÂ Inc"
Description="Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of immuno-oncology therapies for patients. The company is headquartered in Cambridge, Massachusetts."
CIK="1808865"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="139 MAIN STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="410210000"
EBITDA="-63267000"
PERatio="39.55"
PEGRatio="None"
BookValue="17.43"
DividendPerShare="0"
DividendYield="0"
EPS="0.29"
RevenuePerShareTTM="2.411"
ProfitMargin="-0.33"
OperatingMarginTTM="-0.746"
ReturnOnAssetsTTM="-0.0528"
ReturnOnEquityTTM="-0.0451"
RevenueTTM="85987000"
GrossProfitTTM="267630000"
DilutedEPSTTM="0.29"
QuarterlyEarningsGrowthYOY="-0.886"
QuarterlyRevenueGrowthYOY="-0.917"
AnalystTargetPrice="39.75"
TrailingPE="39.55"
ForwardPE="12.56"
PriceToSalesRatioTTM="1.681"
PriceToBookRatio="1.187"
EVToRevenue="0.0111"
EVToEBITDA="0.0154"
Beta="1.167"
num_52WeekHigh="24.39"
num_52WeekLow="11.39"
num_50DayMovingAverage="13.47"
num_200DayMovingAverage="16.41"
SharesOutstanding="35763700"
DividendDate="None"
ExDividendDate="None"
symbol="ITOS"
open="11.77"
high="11.85"
low="11.39"
price="11.43"
volume="215713.00"
latest_trading_day="2023-08-21"
previous_close="11.84"
change="-0.41"
change_percent="-3.4628%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="80"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="20"
Volume_recent_avg="260107"
Change_recent_avg="-0.04"
Delta_recent_avg="0.66"
Variance_recent_avg="0.33"
Change_ratio_recent_avg="-0.35"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="20"
Aroon_momentum_negative="80"
image_negative_thumbnail_id_1="167"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0009.jpeg"
image_negative_thumbnail_id_2="517"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0088.jpeg"
image_neutral_thumbnail_id_1="591"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0008.jpeg"
image_neutral_thumbnail_id_2="589"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0010.jpeg"
image_positive_thumbnail_id_1="615"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0093.jpeg"
image_positive_thumbnail_id_2="704"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0004.jpeg"
image_professor_thumbnail_id_1="1198"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
image_professor_thumbnail_id_2="1184"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
